FPA 144

Drug Profile

FPA 144

Alternative Names: FPA144

Latest Information Update: 12 Jun 2017

Price : $50

At a glance

  • Originator Five Prime Therapeutics
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; Immunostimulants; Type-2 fibroblast growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 03 Jun 2017 Updated efficacy and safety data from a phase I trial in Solid tumours presented at the annual meeting of American Society of Clinical Oncology (ASCO-2017)
  • 03 Jun 2017 Five Prime Therapeutics plans a clinical trial for Gastric cancer (Combination therapy, First-line therapy) in
  • 04 May 2017 Five Prime Therapeutics plans a phase I trial for Gastric cancer in Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top